These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26724940)

  • 1. Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
    Berges C; Chatterjee M; Topp MS; Einsele H
    Immunol Res; 2016 Jun; 64(3):687-98. PubMed ID: 26724940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs.
    Berges C; Bedke T; Stuehler C; Khanna N; Zehnter S; Kruhm M; Winter N; Bargou RC; Topp MS; Einsele H; Chatterjee M
    J Leukoc Biol; 2015 Dec; 98(6):1091-105. PubMed ID: 26265781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M; Bakar-Ates F
    Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.
    Stuehler C; Mielke S; Chatterjee M; Duell J; Lurati S; Rueckert F; Einsele H; Bargou RC; Topp MS
    Blood; 2009 Sep; 114(13):2829-36. PubMed ID: 19657113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
    Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
    Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
    Hugle M; Belz K; Fulda S
    Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.
    Degenhardt Y; Greshock J; Laquerre S; Gilmartin AG; Jing J; Richter M; Zhang X; Bleam M; Halsey W; Hughes A; Moy C; Liu-Sullivan N; Powers S; Bachman K; Jackson J; Weber B; Wooster R
    Mol Cancer Ther; 2010 Jul; 9(7):2079-89. PubMed ID: 20571075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
    Qian Y; Hua E; Bisht K; Woditschka S; Skordos KW; Liewehr DJ; Steinberg SM; Brogi E; Akram MM; Killian JK; Edelman DC; Pineda M; Scurci S; Degenhardt YY; Laquerre S; Lampkin TA; Meltzer PS; Camphausen K; Steeg PS; Palmieri D
    Clin Exp Metastasis; 2011 Dec; 28(8):899-908. PubMed ID: 21953073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
    Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
    Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.